News

If a dividend stock is struggling and falling in value, that pushes its yield up. This happens because while you are getting the same dividend, it is now costing you less money to acquire it. As

If a dividend stock is struggling and falling in value, that pushes its yield up. This happens because while you are getting the same dividend, it is now costing you less money to acquire it. As

Biotech giant Amgen (NASDAQ: AMGN) isn't starting the year on a strong note. The company's shares are down by 5% since Jan. 1. It has dealt with some issues lately, especially subpar financial

Biotech giant Amgen (NASDAQ: AMGN) isn't starting the year on a strong note. The company's shares are down by 5% since Jan. 1. It has dealt with some issues lately, especially subpar financial

Biotech giant Amgen (NASDAQ: AMGN) isn't starting the year on a strong note. The company's shares are down by 5% since Jan. 1. It has dealt with some issues lately, especially subpar financial

Viking Therapeutics' (NASDAQ: VKTX) stock is up an eye-popping 860% over the last three years, with the lion's share of those gains occurring in the last few months. The biotech's pursuit of

Pfizer (NYSE: PFE) has seen its better days. Shares of the big drugmaker have plunged more than 50% from the highs set in late 2021. The pharma stock is down more than 30% over the last 12 months

Pfizer (NYSE: PFE) has seen its better days. Shares of the big drugmaker have plunged more than 50% from the highs set in late 2021. The pharma stock is down more than 30% over the last 12 months

There are many ways to spend $1,000. One could buy a brand-new flat-screen television, play the lottery, or keep it in a savings account. For people trying to increase their capital, though

There are many ways to spend $1,000. One could buy a brand-new flat-screen television, play the lottery, or keep it in a savings account. For people trying to increase their capital, though

There are many ways to spend $1,000. One could buy a brand-new flat-screen television, play the lottery, or keep it in a savings account. For people trying to increase their capital, though

Today, Viking Therapeutics (NASDAQ: VKTX) has no products, no revenue, and happily, almost no debt. By early 2029, the odds are good that none of those factoids will still be true if the biotech is

Investors can be procrastinators. It's easy to get caught up in analyzing stocks so much that people put off buying them. But that doesn't have to be the case.

Three Motley Fool contributors have

Investors can be procrastinators. It's easy to get caught up in analyzing stocks so much that people put off buying them. But that doesn't have to be the case.

Three Motley Fool contributors have

Investors can be procrastinators. It's easy to get caught up in analyzing stocks so much that people put off buying them. But that doesn't have to be the case.

Three Motley Fool contributors have

Finding high-yielding companies isn't everything when investing in dividend stocks. Sometimes, companies' yields increase after their share prices drop significantly, which can occasionally be a

Viking Therapeutics (NASDAQ: VKTX) has been one of the hottest healthcare stocks of 2024. Shares of the company have risen by 285% thus far, and that's even factoring in a recent pullback in price

Finding stocks that can triple in two years is hard enough. Finding those that can do so in a mere two months is that much more impressive. That's precisely what Viking Therapeutics (NASDAQ: VKTX)

The stock market is at record levels these days, but one company that isn't reflecting that optimism is Pfizer (NYSE: PFE). Shares of the pharma giant are down 28% over the past 12 months as

The stock market is at record levels these days, but one company that isn't reflecting that optimism is Pfizer (NYSE: PFE). Shares of the pharma giant are down 28% over the past 12 months as

Two companies stand at the center of the obesity drug market right now. Novo Nordisk continues to rake in money from its weight-loss drug Wegovy (and from off-label usage of its type 2 diabetes drug

Two companies stand at the center of the obesity drug market right now. Novo Nordisk continues to rake in money from its weight-loss drug Wegovy (and from off-label usage of its type 2 diabetes drug

The final set of results for Coherus Biosciences' (NASDAQ: CHRS) 2023 was released after market hours on Wednesday, and investors reacted with displeasure the following day. They traded the stock

Image source: The Motley Fool.

Agenus (NASDAQ: AGEN)Q4 2023 Earnings CallMar 14, 2024, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com